sulfaphenazole has been researched along with Myocardial Infarction in 4 studies
Sulfaphenazole: A sulfonilamide anti-infective agent.
sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to establish the cardioprotective effect of sulfaphenazole (SPZ), a selective inhibitor of cytochrome P450 2C9 enzyme, in an in vivo rat model of acute myocardial infarction (MI)." | 7.75 | Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. ( Hamlin, RL; Khan, M; Kotha, SR; Kuppusamy, P; Kutala, VK; Mohan, IK; Parinandi, NL, 2009) |
| "The objective of this study was to establish the cardioprotective effect of sulfaphenazole (SPZ), a selective inhibitor of cytochrome P450 2C9 enzyme, in an in vivo rat model of acute myocardial infarction (MI)." | 3.75 | Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. ( Hamlin, RL; Khan, M; Kotha, SR; Kuppusamy, P; Kutala, VK; Mohan, IK; Parinandi, NL, 2009) |
| " In addition, SPZ treatment showed significantly decreased superoxide levels and enhanced NO bioavailability in the reperfused heart." | 1.34 | Cardioprotection by sulfaphenazole, a cytochrome p450 inhibitor: mitigation of ischemia-reperfusion injury by scavenging of reactive oxygen species. ( Khan, M; Kumbala, D; Kuppusamy, P; Kutala, VK; Mohan, IK, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adebesin, AM | 1 |
| Wesser, T | 1 |
| Vijaykumar, J | 1 |
| Konkel, A | 1 |
| Paudyal, MP | 1 |
| Lossie, J | 1 |
| Zhu, C | 1 |
| Westphal, C | 1 |
| Puli, N | 1 |
| Fischer, R | 1 |
| Schunck, WH | 1 |
| Falck, JR | 1 |
| Khan, M | 2 |
| Mohan, IK | 2 |
| Kutala, VK | 2 |
| Kotha, SR | 1 |
| Parinandi, NL | 1 |
| Hamlin, RL | 1 |
| Kuppusamy, P | 2 |
| Ishihara, Y | 1 |
| Sekine, M | 1 |
| Hamaguchi, A | 1 |
| Kobayashi, Y | 1 |
| Harayama, T | 1 |
| Nakazawa, M | 1 |
| Shimamoto, N | 1 |
| Kumbala, D | 1 |
4 other studies available for sulfaphenazole and Myocardial Infarction
| Article | Year |
|---|---|
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship | 2019 |
Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation.
Topics: Animals; Biological Availability; Blood Pressure; Blotting, Western; Cardiotonic Agents; Disease Mod | 2009 |
Effects of sulfaphenazole derivatives on cardiac ischemia-reperfusion injury: association of cytochrome P450 activity and infarct size.
Topics: Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Electron Spin Resonan | 2010 |
Cardioprotection by sulfaphenazole, a cytochrome p450 inhibitor: mitigation of ischemia-reperfusion injury by scavenging of reactive oxygen species.
Topics: Animals; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Free Radical Scaven | 2007 |